Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
10.78 USD | +2.76% | -6.83% | -12.00% |
Sales 2024 * | - | Sales 2025 * | 16.49M 1.32B | Capitalization | 455M 36.32B |
---|---|---|---|---|---|
Net income 2024 * | -114M -9.11B | Net income 2025 * | -110M -8.79B | EV / Sales 2024 * | - |
Net cash position 2024 * | 218M 17.44B | Net cash position 2025 * | 105M 8.36B | EV / Sales 2025 * | 21.2 x |
P/E ratio 2024 * |
-3.55
x | P/E ratio 2025 * |
-4.51
x | Employees | 118 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.86% |
Latest transcript on KalVista Pharmaceuticals, Inc.
1 day | +2.76% | ||
1 week | -6.83% | ||
Current month | -9.11% | ||
1 month | -9.11% | ||
3 months | -19.37% | ||
6 months | +34.92% | ||
Current year | -12.00% |
Managers | Title | Age | Since |
---|---|---|---|
Ed Feener
FOU | Founder | 64 | 25/03/04 |
Ben Palleiko
CEO | Chief Executive Officer | 58 | 31/07/16 |
Paul Audhya
CTO | Chief Tech/Sci/R&D Officer | 51 | 02/05/21 |
Members of the board | Title | Age | Since |
---|---|---|---|
Brian Pereira
CHM | Chairman | 65 | 31/01/19 |
Ben Palleiko
CEO | Chief Executive Officer | 58 | 31/07/16 |
Albert Cha
BRD | Director/Board Member | 51 | 31/12/15 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.04% | 2 M€ | -.--% | ||
0.03% | 0 M€ | 0.00% | - | |
0.00% | 9 M€ | +6.26% | - |
Date | Price | Change | Volume |
---|---|---|---|
26/04/24 | 10.78 | +2.76% | 241,417 |
25/04/24 | 10.49 | +1.35% | 363,775 |
24/04/24 | 10.35 | -7.67% | 482,332 |
23/04/24 | 11.21 | -2.01% | 192,501 |
22/04/24 | 11.44 | -1.12% | 289,249 |
Delayed Quote Nasdaq, April 26, 2024 at 09:00 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-12.00% | 455M | |
-4.53% | 86.13B | |
+1.32% | 39.82B | |
-19.27% | 30.42B | |
+57.86% | 25.23B | |
-16.09% | 15.36B | |
-9.14% | 11.95B | |
-17.69% | 11.6B | |
-43.00% | 11.51B | |
+5.24% | 8.71B |
- Stock Market
- Equities
- KALV Stock